{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-21-004081","form_type":"8-K","ticker":"LONA","cik":"0001620463","company_name":"LeonaBio, Inc.","filed_at":"2021-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:04:13.358206+00:00","generated_at":"2026-06-28T09:58:07.572636+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Athira Pharma Q3 net loss $15.7M; ACT-AD trial enrollment completed","bullets":["Net loss of $15.7M ($0.42 per share) vs $8.5M loss in Q3 2020; R&D spend $10.7M.","Cash, cash equivalents and investments $339.4M as of Sept 30, 2021, up from $268.2M at Dec 31, 2020.","Completed enrollment in Phase 2 ACT-AD trial (77 subjects); topline data expected H1 2022.","LIFT-AD Phase 2/3 actively recruiting; topline data expected by end of 2022.","SHAPE Phase 2 trial (Parkinson's dementia) anticipated to initiate by end of 2021; IND for ATH-1020 expected by end of 2021."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-21-004081","json":"https://secwatch.observer/filing/0000950170-21-004081.json","markdown":"https://secwatch.observer/filing/0000950170-21-004081.md","text":"https://secwatch.observer/filing/0000950170-21-004081.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1620463/000095017021004081/0000950170-21-004081-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1620463/000095017021004081/atha-20211110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-28T09:58:07.572636+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}